AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00892866 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01743144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
Study NCT01743144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
Study NCT03983239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Fedratinib
Study NCT03983239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin
Study NCT02213042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Lapatinib is available as 250-mg orange tablets. Subjects randomized to the Lapatinib plus Trastuzumab arm received 1000 mg per day of Lapatinib, so wre instructed to take 4 x 250 mg tablets per day. Lapatinib was to be taken either 1 hour (or more) before a meal or 1 hour (or more) after a meal
Study NCT02213042 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab is a sterile, white to pale yellow, preservative-free lyophilized powder for IV administration. Trastuzumab was administered on Day 1 of the start of Lapatinib or in conjunction with the first cycle of chemotherapy, as an 8 mg/kg loading dose. Subsequently, Trastuzumab was administered q3weekly as a 6 mg/kg maintenance dose. At the discretion of the investigator, weekly Trastuzumab could be given in either of the three treatment arms (loading dose 4mg/kg followed by weekly administration of 2mg/kg).
Study NCT02213042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitors (AIs)
Description: Subjects who were hormone receptor-positive were required to receive an aromatase inhibitor as combination treatment; however the choice of the aromatase inhibitor selected for each patient was determined by the patients' investigator. The AIs the Investigator could choose from were anastrozole, exemestane, and letrozole and dosing was per product information.
Study NCT02448186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESTEEM
Description: 10-session cognitive behavioral treatment
Study NCT01632917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101 - U.S.
Description: US ATX-101, 10 mg/mL, one dosing session in the submental area
Study NCT01632917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101 - EU
Description: EU ATX-101, 10 mg/mL, one dosing session in the submental area
Study NCT03793556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GERDOFF® + Omeprazole
Description: GERDOFF® Hyaluronic acid + chondroitin sulphate + hydroxide aluminium Melt-in-mouth tablet 1100 mg + Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).
Study NCT03793556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole, 2 capsules 20 mg, once a day before breakfast
Study NCT02846233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP1 receptor agonist
Description: Albiglutide or Dulaglutide will be added to a basal insulin.
Study NCT02846233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basal insulin
Description: The participant will continue with the basal insulin.
Study NCT02846233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Empagliflozin will be added to a basal insulin.
Study NCT02846233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The participant will continue with metformin.
Study NCT03983239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz
Study NCT01842347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota
Study NCT03441984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: DTG and 3TC (Adult), administered as a, single dose, Single dose, 1 tablet DTG (50 mg) and~1 tablet 3TC (300 mg), orally as direct-to-mouth.
Study NCT03441984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as 10 dispersible tablets.
Study NCT04519567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTI-1601
Description: CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
Study NCT04519567 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT02840240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil
Description: 600 mg BID 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg BID 3 days post-operative
Study NCT02840240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 600 mg BID taken 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg 3 days post-operative
Study NCT03207893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GEM lifestyle modification & continuous glucose monitoring
Description: Four treatment sessions of GEM lifestyle modification in 3 months and continuous glucose monitoring during the first 14 days of each of the 3 months.
Study NCT03207893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Care
Description: Subject's current t2d treatment
Study NCT03207893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Subject's current t2d treatment
Study NCT03441984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as direct-to-mouth.
Study NCT03770611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The probiotic supplement is composed of the following bacterial strains: Bacillus coagulans, Bacillus subtilis, Bifidobacterium (B) bifidum, B. breve, B. longum, Lactobacillus (L) acidophilus, L. brevis, L. casei, L. helveticus, L. Paracasei, L plantarum, L. rhamnosus, L. salivarus, Lactococcus lactis, Pediococcus acidilactici, Pediococcus parvulus, Weisella confusa, Weisella paramesenteroides
Study NCT03770611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic
Description: The prebiotic fiber is Agave inulin
Study NCT03770611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Symbiotic
Description: The supplement is a combination of the probiotic product + the prebiotic fiber
Study NCT03645356 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed Appliances
Description: Using an MBT-prescription of metallic brackets, patients will be treated in the conventional way
Study NCT03645356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear Aligners
Description: Using a sequence of clear aligners, patients will be give an aligner every two weeks until the completion of treatment
Study NCT00082719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa
Description: In all arms, treatment begins at pre-operative visit and continues until cystoscopy.~Arm I: Low-dose interferon alfa subcutaneously (SC) twice daily. Arm II: Interferon alfa as in arm I at a higher dose. Arm III: Interferon alfa SC once daily. Arm IV: Interferon alfa as in arm III at a higher dose.
Study NCT02469064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training
Description: Respiratory muscle training is done twice every day, with 3 series of 10 repetitions each, with a resting pause of two minutes between series (during resting time, patient is connected to mechanical ventilation again). We adjust initial load for respiratory muscle training as 50% of MIP. At the end of every training session, we assess dyspnea (perceived effort) using Modified Borg Scale (23). Four physical therapists are in charge of Respiratory muscle training, these therapists work at ICU and have experience with critically ill patients.
Study NCT03770611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The supplement is a combination of probiotic placebo and prebiotic fiber placebo. Placebo will consist on maltodextrin for both cases.
Study NCT00860496 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CP- 690,550 and Tacrolimus
Description: 10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8
Study NCT01815983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy review.
Description: Review of video recordings.
Study NCT00860496 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CP- 690,550 and Cyclosporine
Description: 10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6
Study NCT01654861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)
Description: Weeks 1,2,3: IV Gemcitabine 1000 mg / m² over 30 minutes followed by HDIVC 1.2 g / kg: 1.2 g/kg over 90 minutes for a dose ≤90 g and over 120 minutes for a dose >90g followed by 0.3 g / kg over 120 minutes; Week 4: no treatment.
Study NCT03004196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Toothpaste
Description: G.D Probiotic Toothpaste bacteriocin Lactic Acid Bacteria
Study NCT03004196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dr. Reddy's Clohex
Description: 0.20% Chlorhexidine Mouthwash
Study NCT03004196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: No Probiotic toothpaste \& Chlorhexidine Mouthwash
Study NCT00265122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: one 90 mg SC injection each week for 4 weeks (Weeks 0-3 during Intervention Period 1 or Weeks 8-11 during Intervention Period 2 for Population 1 or Weeks 0-3 during Intervention Period 1 for Population 2)
Study NCT03253458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscopy
Description: Transperineal confocal laser endomicroscopy or optical coherence tomography measurements. Probe will be placed guided by ultrasound, similar procedure as transperineal template guided mapping biopsies.
Study NCT02469064 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Physical Therapy
Description: Control group receives Cardiopulmonary Physical Therapy every 6 hours, physical therapy and mechanical ventilation management
Study NCT02469064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Physical Therapy
Description: Control group receives Cardiopulmonary Physical Therapy every 6 hours, physical therapy and mechanical ventilation management
Study NCT04499976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isonicotinic Acid
Description: Drug: Isonicotinic Acid then misoprostol Drug: Isonicotinic Acid 300mg total dose 900 mg per day for 3 days
Study NCT04499976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: placebo then misoprostol Drug: Placebo placebo for 3 days
Study NCT04499976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion
Study NCT04499976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion
Study NCT02682407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OMS721 (narsoplimab)
Description: Biological: OMS721 (narsoplimab)
Study NCT02126358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin and/or Rosuvastatin
Study NCT02126358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemigliptin and/or Rosuvastatin
Study NCT02725645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: loading conditions
Description: Different backpack loading conditions 0%, 10%, 15% and 20% allocated randomly
Study NCT03065699 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DIALIVE Liver Dialysis Device
Description: ACLF patients will receive dialysis treatment for 8-12 hrs/day and on three to five consecutive days over a 10-day time period. Dialysis treatment is performed by using the DIALIVE device provided by YAQRIT Ltd.
Study NCT04035954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The control group will continue the routine NDT: Neurodevelopmental Therapy-based physiotherapy program twice a week. The treatment group will participate in clinical pilates exercises for 2 hours / day for 1 hour / 8 weeks. They will also continue their weekly routine physiotherapy programs.
Study NCT04035954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: The control group will continue the routine NDT: Neurodevelopmental Therapy-based physiotherapy program twice a week. The treatment group will participate in clinical pilates exercises for 2 hours / day for 1 hour / 8 weeks. They will also continue their weekly routine physiotherapy programs.
Study NCT02855840 — intervention group
Intervention type: OTHER
Intervention: completion of the quality of life questionnaire
Study NCT02045355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fish intervention
Description: The intervention will compare fish intake with a correspondent amount of meat. The basis for the comparison will be the estimated protein intake from fish and meat and should be almost similar both from fish and from meat. To ensure compliance and to add more variety to the diet, different fish types will be included in the intervention group and different meat sources in the control group. The types of fish (and that of meat in the control diet) that will be used will be accurately documented and will be similar for all participants included.
Study NCT00265122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 4.5 mg/kg
Description: one IV infusion of 4.5 mg/kg over a period of not less than 2 hours at Week 0 in Intervention Period 1 or Week 8 in Intervention Period 2 for Population 1 or at Week 0 in Intervention Period 1 for Population 2
Study NCT04672720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine 1000 Mg
Description: Prescription 3mg l-carnitine (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) daily from day 2 of the previous menstrual cycle until pregnancy test day (approximately 8 weeks).
Study NCT04672720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-carnitine 1000 Mg
Description: Prescription 3mg l-carnitine (L-carnitine® tablet 1000 mg, Karen Pharmaceutical Company, Iran) daily from day 2 of the previous menstrual cycle until pregnancy test day (approximately 8 weeks).
Study NCT00265122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: one SC injection each week for 4 weeks (Weeks 0-3 in Intervention Period 1 or Weeks 8-11 in Intervention Period 2 for Population 1 or at Weeks 0-3 in Intervention Period 1 for Population 2)
Study NCT03267927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion
Description: Fixation of rapid palatal expansion from day 0 to day 60
Study NCT03267927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGA™ system
Description: Use of a mandibular advancement Appliance during the night from day 60 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
Study NCT03267927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yoobreath™ system
Description: Use of a device allowing sleep in a semi-seated position during the night from day 15 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
Study NCT04874363 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT01414166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERN/LRPT
Description: ERN/LRPT combination tablets (each containing 1 g of extended release niacin and 20 mg of laropiprant), orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
Study NCT01414166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: ERN/LRPT-matched placebo, orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
Study NCT00258284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
Study NCT00258284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
Study NCT04379544 — intervention group
Intervention type: OTHER
Intervention: Observation only
Description: There is no intervention. This study is purely observational. This study simply follows COVID-19 patients who get CPUS based on their clinician deeming it necessary.
Study NCT02404467 — intervention group
Intervention type: DEVICE
Intervention: TF TAVI
Description: Follow-up Observation of patients having received a TF-TAVI
Study NCT01331733 — intervention group
Intervention type: DRUG
Intervention: hMG-HP
Study NCT01331733 — intervention group
Intervention type: DRUG
Intervention: hMG + GnRH antagonist
Study NCT00882466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human recombinant erythropoietin
Description: intravenous bolus injection of EPO (50unit/kg)
Study NCT01877018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic reminder
Description: Electronic reminder introduced into primary care medical health record, identifying invited people to the population-based colorectal cancer screening program, to promote their participation.
Study NCT00958568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine and Fluoxetine combination (OFC)
Description: Open label acute phase: introductory dose for 4 days then 3 milligram (mg) Olanzapine and 25 mg Fluoxetine Combination (3/25), 6/25, 12/25, 6/50, 12/50 or 18/50, oral, daily, for 6-8 weeks.~Open label stabilization phase: 6/25, 12/25, 6/50, 12/50 or 18/50 mg, oral, daily for 16-20 weeks.~Double blind relapse prevention phase: dose determined during stabilization phase at Week 17, oral, daily, for 27 weeks.
Study NCT00958568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: 25 or 50 mg/day fixed dosing for 27 weeks
Study NCT04088513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: This group will receive a 100 mg/day aspirin plus clopidogrel placebo for 90 days.
Study NCT04088513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: This group will receive a 75 mg/day clopidogrel plus aspirin placebo for 90 days.
Study NCT01102322 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality
Description: Factors associated with the use of lung protective ventilation strategy (LPV) in ALI/ARDS patients in ICU
Study NCT01279031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound
Description: Comparison of vision after cataract surgery based on two different types of equipment.
Study NCT02973529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorb
Description: Randomization to implantation of Absorb BVS in bifurcation lesion
Study NCT02973529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Desolve
Description: Randomization to implantation of Desolve BRS in bifurcation lesion
Study NCT01279031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcon Infiniti wiht the OZIL Torsional Handpiece
Description: Comparision of vision after cataract surgery based on two different types of equipment.
Study NCT02938039 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu LMA
Description: Ambu Laryngeal Mask Airways
Study NCT02938039 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-Gel LMA
Description: I-Gel Laryngeal Mask Airways
Study NCT00261118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 1g in 500 mls Normal Saline Placebo 500 mls Normal Saline